Posted on 09/22/2024 8:09:36 PM PDT by ConservativeMind
Findings from the international FORT-2 clinical trial showed a combination treatment including immunotherapy is safe and tolerable in patients with locally advanced or metastatic bladder cancer.
In urothelial bladder cancer, increased T cell infiltration has been correlated with longer patient survival.
In many cases, fibroblast growth factor receptor (FGFR) mutations are known to be drivers of bladder cancer development and progression.
"In 2016, we published studies showing that the tumors with FGFR3 mutations have no T cell infiltration, which led to the logical conclusion that blocking the FGFR pathway could make more patients responsive to immunotherapy," said Sweis.
Previous clinical studies with an FGFR inhibitor, rogaratinib, demonstrated that the treatment is tolerable and could shrink tumors in patients. In pre-clinical cancer models, the combination of FGFR inhibitor and a programmed cell death ligand 1 (PD-L1) inhibitor showed increased survival and antitumor activity.
FORT-2 is a phase 1b/2 non-randomized clinical trial. It is the first clinical trial to evaluate the safety, tolerability and the recommended phase 2 dose of FGFR inhibitor plus PD-L1 inhibitor in advanced urothelial cancer patients with FGFR mRNA high expression.
"By measuring FGFR mRNA gene expression, we found that half of the patients' tumors have activation of the FGFR pathway, whereas previous studies reported only about 15% using a method that measured only FGFR DNA mutations, suggesting overexpression of FGFR captures all mutations and additional tumors where this pathway is relevant," said Sweis.
In previous studies, the response rate reported was 23% with PD-L1 inhibitor, atezolizumab alone and 21% with rogaratinib alone; however, by combining the FGFR inhibitor and PD-L1 inhibitor, the response rate increased to 54%. In addition, the responses were achieved quickly, with a median time to response of 2.1 months, and included many durable responses lasting longer than 2 years.
(Excerpt) Read more at medicalxpress.com ...
I know an Australian lady who achieved remission for her bladder cancer using Ivermectin based therapy.
Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage
And get a load of this...
Results: Our study showed that in vitro and in vivo, Ivermectin inhibited the growth of bladder cancer cells. In addition, Ivermectin could induce apoptosis, ROS production, DNA damage, and activate ATM/P53 pathwayrelated proteins in bladder cancer cells.
Wowza!
...full text...
Why they (TPTB ... FRAUDci, BigPharma, $hot $hills) didn’t want any of US taking IVM!!
Stops/prevents too many (turbo/other) cancers that they make $$ on.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.